


# Schedule of Accreditation

issued by

## United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

|   |  |  |
|---|--|--|
|  <p>1636</p> <p>Accredited to<br/>ISO/IEC 17025:2017</p> | <h3>Drug Control Centre – King’s College London</h3> <p>Issue No: 040 Issue date: 26 March 2020</p>    |  |
|   | <p>The Franklin-Wilkins Building<br/>150 Stamford Street<br/>London<br/>SE1 9NH<br/>United Kingdom</p> | <p>Contact: Gillian Knight<br/>Tel: +44 (0)20 7848 4848<br/>Fax: +44 (0)20 7848 4980<br/>E-Mail: gillian.knight@kcl.ac.uk<br/>Website: www.kcl.ac.uk/dcc</p> |
| <p>Testing performed at the above address only</p>  |  |  |

### DETAIL OF ACCREDITATION

| Materials/Products tested | Type of test/Properties measured/Range of measurement   | Standard specifications/ Equipment/Techniques used  |
|---------------------------|---|---|
| BODY FLUIDS               | <u>Physical - Chemical Analysis</u>   | Documented In house methods in accordance with WADA International Standard for Laboratories (ISL)   |
| Human Urine               | pH  | Sample integrity check using pH meter (SOP9)  |
|                           | Specific gravity  | Sample Integrity check using refractometer (SOP9)   |
|                           | <u>Chemical Analysis</u>  |   |
| Human Urine               | Initial Testing Procedures and Qualitative Confirmation Procedures of substances prohibited by the World Anti Doping Agency (WADA) Including: | Flexible scope (SOP13) using LC and GC coupled to mass spectrometry e.g. LC-MS, GC-MS, LCMS/MS, GCMS/MS, using procedures SOP4, SOP5, SOP6, SOP18 |
|                           | S0 Non-approved Substances.   |   |
|                           | S1 Anabolic agents (including 19-norandrosterone)   |   |
|                           | S3 Beta-2 Agonists (b2ag)   |   |
|                           | S2/S4 Hormone antagonists and metabolic modulators (including detection of gene doping agents)  |   |
|                           | S5 Diuretics and other masking agents, including plasma expanders   |   |
|                           | M1 Enhancement of oxygen transfer (e.g. Efaproxiral RSR13)  |   |
|                           | S6 Stimulants   |   |
|                           | S7 Narcotics  |   |
|                           | S8 Cannabinoids   |   |
|                           | S9 Glucocorticoids  |   |
|                           | P1 Beta Blockers  |   |
|                           | Alcohol Markers: (Ethyl glucuronide, Ethyl Sulphate)  | LC-MS (SOP6)  |



1636  
Accredited to  
ISO/IEC 17025:2017

**Schedule of Accreditation**  
issued by  
**United Kingdom Accreditation Service**  
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

**Drug Control Centre – King’s College London**  
**Issue No: 040 Issue date: 26 March 2020**

**Testing performed at main address only**

| Materials/Products tested             | Type of test/Properties measured/Range of measurement   | Standard specifications/ Equipment/Techniques used  |
|---------------------------------------|---|---|
| BODY FLUIDS (cont'd)                  | <u>Chemical Analysis</u> (cont'd)   | Documented In house methods In accordance with WADA International Standard for Laboratories (ISL)   |
| Human Urine and Blood (Serum, Plasma) | Initial Testing Procedures and Qualitative Confirmation Procedures of substances prohibited by the World Anti Doping Agency (WADA) Including:<br>S2 Erythropoiesis Stimulating Agents<br>e.g. Erythropoietin (EPO), darbepoetin (dEPO), CERA (Continuous Erythropoiesis Receptor Activator) | Flexible scope (SOP13) using Immunopurification, gel electrophoresis with immunoblotting and luminescence detection e.g. Sarcosyl PAGE<br><br>Immunopurification, gel electrophoresis with immunoblotting and luminescence detection e.g. Sarcosyl PAGE (SOP20) |
| Human Urine                           | S2 Human chorionic gonadotrophin (hCG) – Screening only.  | Chemiluminescence (Immulite) for total hCG and Immunoassay two-site fluoroimmunoassay for intact hCG (SOP7)   |
| Human Urine                           | S2 Luteinizing Hormone  | Immunoassay;<br>Chemiluminescence (Immulite) (SOP7)   |
| Human Urine                           | Initial Testing Procedures and Qualitative Confirmation Procedures of substances prohibited by the World Anti Doping Agency (WADA) Including:<br><br>S1 Anabolic agents such as; Testosterone<br>Epi-testosterone including determination of T/E ratio (endogenous steroid profile)         | Flexible scope (SOP13) using gas chromatography coupled to mass spectrometry (GC-MS and GC-MS/MS) and Gas Chromatography Combustion Isotope Ratio Mass Spectrometry (GC-C-IRMS)<br>GC-MS, GC-MS/MS, GC-C-IRMS (SOP5), (SOP11)                                   |
| Human Urine and Blood (Serum, Plasma) | Initial Testing Procedures and Qualitative Confirmation Procedures of substances prohibited by the World Anti Doping Agency (WADA) Including:<br>S2 Proteins and peptide hormones (e.g. Insulin analogue “Humalog”)   | Flexible scope (SOP13) using liquid chromatography coupled to mass spectrometry (LC-MS and LC-MS/MS)<br><br>LC-MS and LC-MS/MS (SOP18)  |



1636  
Accredited to  
ISO/IEC 17025:2017

**Schedule of Accreditation**  
issued by  
**United Kingdom Accreditation Service**  
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

**Drug Control Centre – King’s College London**  
**Issue No: 040 Issue date: 26 March 2020**

Testing performed at main address only

| Materials/Products tested | Type of test/Properties measured/Range of measurement   | Standard specifications/ Equipment/Techniques used  |
|---------------------------|---|---|
| BODY FLUIDS (cont'd)      | <u>Chemical Analysis</u> (cont'd)   | Documented In house methods In accordance with WADA International Standard for Laboratories (ISL) |
| Human Urine               | S2 Proteins and peptide hormones (e.g. Growth Hormone Releasing Factors)  | LC-MS and LC-MS/MS (SOP18)  |
| Human Urine               | Quantitative Confirmation Procedures of threshold substances prohibited by the World Anti Doping Agency (WADA): |   |
|                           | Salbutamol  | liquid chromatography coupled to mass spectrometry (LC-MS/MS) (SOP6)                              |
|                           | Formoterol  | liquid chromatography coupled to mass spectrometry (LC-MS/MS) (SOP6)                              |
|                           | Cathine   | liquid chromatography coupled to mass spectrometry (LC-MS/MS) (SOP6)                              |
|                           | Ephedrine   | liquid chromatography coupled to mass spectrometry (LC-MS/MS) (SOP6)                              |
|                           | Methylephedrine   | liquid chromatography coupled to mass spectrometry (LC-MS/MS) (SOP6)                              |
|                           | Pseudoephedrine   | liquid chromatography coupled to mass spectrometry (LC-MS/MS) (SOP6)                              |
|                           | Morphine  | liquid chromatography coupled to mass spectrometry (LC-MS/MS) (SOP6)                              |
|                           | Carboxy THC   | Gas chromatography coupled to mass spectrometry (GC-MS/MS) (SOP6)                                 |



1636  
Accredited to  
ISO/IEC 17025:2017

**Schedule of Accreditation**  
issued by  
**United Kingdom Accreditation Service**  
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

**Drug Control Centre – King’s College London**  
**Issue No: 040 Issue date: 26 March 2020**

Testing performed at main address only

| Materials/Products tested | Type of test/Properties measured/Range of measurement  | Standard specifications/ Equipment/Techniques used  |
|---------------------------|--|---|
| BODY FLUIDS (cont'd)      | <u>Chemical Analysis</u> (cont'd)  | Documented In house methods In accordance with WADA International Standard for Laboratories (ISL)   |
| Human Blood (Serum)       | Initial Testing Procedures and Qualitative Confirmation Procedures:<br><br>Human Growth Hormone (hGH) isoform ratio<br>And<br>HGH biomarkers (IGF- I and P-III-NP) measurement<br><br>Quantitative Confirmation Procedures:<br>IGF-I   | Immunoassay:<br>Luminescence detection<br>Radioimmunoassay (SOP19)                                  |
| Human Blood               | Blood parameters:<br><br>Haemoglobin concentration<br>Percentage of reticulocytes<br>Number of red blood cells (erythrocytes),<br>Number of platelets,<br>Number of reticulocytes,<br>Number of all white blood cells (leucocytes),<br>Haematocrit (erythrocyte ratio of total blood volume)<br>Mean cell (erythrocyte) volume in total sample,<br>Mean haemoglobin volume per<br>Number of all red blood cells,<br>Mean cell (erythrocyte) haemoglobin concentration) | liquid chromatography coupled to mass spectrometry (LC-MS-MS) (SOP19)<br><br>Flow Cytometry (SOP17) |

END